URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


HER2-Targeted Therapies Summit 2022


Date
Jun 14, 2022 - 09:00 AM - Jun 16, 05:00 PM
Organizer
Hanson Wade
Venue
Hyatt Regency Boston
Location
1, Avenue de Lafayette

Boston,
MA,
USA,
ZIP: 02111
Phone: +16174554188

Ticket Price: Industry Pricing - Conference + Workshop Day - Standard Rate: USD 4097.0, Industry Pricing - Conference Only - Standard Rate: USD 2899.0

The momentum in anti-HER2 drug development is exploding:

Outcomes for HER2-expressing breast cancer are patients constantly improving; diagnostics, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 'low' space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before.

As such, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma, biotech and academia to unite under one roof to discuss these developments, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients.

As the clinical and commercial opportunity of HER2-targeted therapies becomes apparent, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target.

Early bird rates are available!

URLs:
Tickets: https://go.evvnt.com/1003520-2?pid=1052
Brochure: https://go.evvnt.com/1003520-3?pid=1052



Speaker Details


Cecile Geuijen Chief Scientific Officer and Vice President - Oncology, Merus, Shane Olwill Chief Development Officer, Senior Vice President and Head of Translational Science, Pieris Pharmaceuticals, Athanasios Tsiatis Senior Vice President - Clinical Development, ALX Oncology, Edith Perez Chief Medical Officer, Bolt Biotherapeutics, Fredrik Frejd Chief Scientific Officer, Affibody, Roger Waltzman Chief Medical Officer, Molecular Templates, Debora Barton Chief Medical Officer, Carisma Therapeutics, Reva Basho Assistant Professor, Breast Medical Oncology, Co-Director: Women's Cancer Research Program, Cedars-Sinai Medical Center, Gail Lewis Phillips Principal Scientist, Discovery Oncology, Genentech, John Strickler Associate Professor of Medicine, Duke Clinical Research Institute, Deyaa Adib Chief Medical Officer, Triumvira Immunologics, Wendy Hauck Global Associate Medical Director, Women's Cancer Care, Eisai, Funda Meric - Bernstam Chair, Department of Investigational Cancer Therapeutics and Medical Director Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Fiore Cattaruzza Senior Director - Pharmacology and Preclinical Development Biomarkers, Amunix Pharmaceuticals, RJ Tesi Chief Executive and Medical Officer, Inmune Bio, Aparna Parikh Assistant Professor and Director, Harvard Medical School and MGH Cancer Center's Global Cancer Care Program, Roxana Schillaci Principal Researcher, Institute of Biology and Experimental Medicine CONICET, Argentina, Kirk Tanner Chief Scientific Officer, National Brain Tumor Society, Jenny Karlsson Head of TRP Biochemistry, Bayer, Teemu Junttila Senior Principal Scientist - Technology and Translational Oncology, Genentech, Serena Masciari Senior Medical Director, Oncology Early Development, Sanofi Genzyme, Paul Rennert President and Chief Scientific Officer, Aleta Biotherapeutics, Nataliya Uboha Medical Oncologist, University of Wisconsin School of Medicine and Public Health

Event Categories
Keywords: pharmaceutical




Comments








Events Calendar

SunMonTueWedThuFriSat
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 1 2

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99